

SECURITIES AND EXCHANGE COMMISSION

FORM 8-K

Current report filing

Filing Date: 2010-06-01 | Period of Report: 2010-05-24  
SEC Accession No. 0000950103-10-001614

(HTML Version on [secdatabase.com](http://secdatabase.com))

FILER

**Shire plc**

CIK: **936402** | IRS No.: **000000000** | Fiscal Year End: **1231**  
Type: **8-K** | Act: **34** | File No.: **000-29630** | Film No.: **10868009**  
SIC: **2834** Pharmaceutical preparations

Mailing Address	Business Address
HAMPSHIRE INTL BUSINESS PARK CHINEHAM BASINGSTOKE HAMPSHIRE ENGLAND RG X0 R924 8EP	HAMPSHIRE INTL BUSINESS PARK CHINEHAM BASINGSTOKE HAMPSHIRE ENGLAND RG X0 R924 8EP 441256894000



Item 8.01. Other Events

Shire plc has issued the press release attached hereto as Exhibit 99.01 which is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits. The following exhibit is filed herewith:

99.01 Press Release dated May 24, 2010

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SHIRE PLC

By: /s/ A C Russell

Name: Angus Russell

Title: Chief Executive Officer

Dated: May 24, 2010

---

## EXHIBIT INDEX

Number	Description
99.01	Press Release dated May 24, 2010

---

# Press Release



[www.shire.com](http://www.shire.com)

## BLOCK LISTING SIX MONTHLY RETURN

**May 24, 2010** - Shire plc (LSE: SHP, NASDAQ: SHPGY)

Name of <i>applicant</i> :	Shire plc		
Name of scheme:	1996 Executive Share Option Scheme		
Period of return:	From:	23 November 2009	To: 22 May 2010
Balance of unallotted securities under scheme(s) from previous return:	81,000		
<i>Plus</i> : The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):	Nil		
<i>Less</i> : Number of <i>securities</i> issued/allotted under scheme(s) during period (see LR3.5.7G):	Nil		
<i>Equals</i> : Balance under scheme(s) not yet issued/allotted at end of period:	81,000		

Name of <i>applicant</i> :	Shire plc		
Name of scheme:	2000 Executive Share Option Scheme		
Period of return:	From:	23 November 2009	To: 22 May 2010
Balance of unallotted securities under scheme(s) from previous return:	4,881,959		
<i>Plus</i> : The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):	Nil		
<i>Less</i> : Number of <i>securities</i> issued/allotted under scheme(s) during period (see LR3.5.7G):	990,762		
<i>Equals</i> : Balance under scheme(s) not yet issued/allotted at end of period:	3,891,197		

Name of <i>applicant</i> :	Shire plc		
Name of scheme:	Shire Sharesave Scheme		
Period of return:	From:	23 November 2009	To: 22 May 2010

Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX

Balance of unallotted securities under scheme(s) from previous return:	32,341
<i>Plus:</i> The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):	Nil
<i>Less:</i> Number of <i>securities</i> issued/allotted under scheme(s) during period (see LR3.5.7G):	26,949
<i>Equals:</i> Balance under scheme(s) not yet issued/allotted at end of period:	5,392

Name of <i>applicant</i> :	Shire plc		
Name of scheme:	Biochem Pharma Stock Option Plan		
Period of return:	From:	23 November 2009	To: 22 May 2010
Balance of unallotted securities under scheme(s) from previous return:	8,999		
<i>Plus:</i> The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):	Nil		
<i>Less:</i> Number of <i>securities</i> issued/allotted under scheme(s) during period (see LR3.5.7G):	3,640		
<i>Equals:</i> Balance under scheme(s) not yet issued/allotted at end of period:	5,359		

Name of contact:	Tony Guthrie, Deputy Company Secretary
Address of contact:	Hampshire International Business Park Basingstoke, Hampshire, RG24 8EP
Telephone number of contact:	01256 894754

**For further information please contact:**

<b>Investor Relations</b>	Cléa Rosenfeld (Rest of the World)	+44 1256 894 160
	Eric Rojas (North America)	+1 781 482 0999

**Notes to editors**

**SHIRE PLC**

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases

**Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX**

as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: [www.shire.com](http://www.shire.com).

---

**Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX**